Paclitaxel Injection

This product is a new type of anti-microtubule drug that promotes tubulin polymerization and inhibits depolymerization, maintains tubulin stability, and inhibits cell mitosis. In vitro experiments have shown that paclitaxel has a significant radiosensitization effect, which may be to stop cells in the G2 and M phases that are sensitive to radiotherapy.

5β,20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytaxane-11-ene-9-one-4,10-diacetate-2-benzoate-13-[(2'R,3'S)-N-benzoyl-3-phenylisoserine ester

This product is a colorless or light yellow clear viscous liquid.

First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.

Before use, dilute this product with normal saline, 5% glucose water or 5% glucose normal saline to 0.31.2mg/ml, and drip for 3 hours. The single drug dose is 135-200mg/m2, and can reach 250mg/m2 with the support of colony stimulating factor (G-CSF). The combined dose is 135175mg/m2, repeated for 34 weeks. When dripping paclitaxel, non-polyvinyl chloride infusion bottles and infusion sets should be used, and the microporous membrane diameter of the filter should be less than 0.22 microns through the connected filter.

1. Allergic reactions: The incidence rate is 39%, of which severe allergic reactions occur in 2%. Most are type 1 allergic reactions, manifested as bronchospasm, dyspnea, urticaria and hypotension. Almost all reactions occur within the first 10 minutes after medication. 2. Bone marrow suppression: It is the main dose-limiting toxicity, manifested as neutropenia, and thrombocytopenia is rare, generally occurring 8 to 10 days after medication. The incidence of severe neutrophilia is 47%, and the incidence of severe thrombocytopenia is 5%. Anemia is more common. 3. Neurotoxicity: The incidence of peripheral neuropathy is 62%, the most common manifestations are mild numbness and paresthesia, and the incidence of severe neurotoxicity is 6%. 4. Cardiovascular toxicity: There may be hypotension and no symptoms

1. Those who are allergic to this product or polyoxyethyl castor oil. 2. Those whose white blood cell count is lower than 1.5×109/L. 3. Pregnant and lactating women.

Precautions for children: Precautions for pregnancy and lactation: Paclitaxel has been shown to affect embryonic growth in animal experiments, so it is contraindicated for pregnant women. Women of childbearing age should not become pregnant during treatment. Precautions for the elderly:

Pharmacokinetic data show that the clearance of this product is reduced by about 30% when it is given after cisplatin, and the bone marrow toxicity is more serious. The simultaneous use of ketoconazole affects the metabolism of this product.

Keep away from light and store in sealed container below 25℃.

16.7ml:100mg

24 months

Wuxi Taxus Pharmaceutical Co., Ltd.

• Founded in:

  2004-05-31

• Address:

  No. 111, Qinxin Road, Donggang Town, Xishan District, Wuxi City

• Tax NO.:

  9132020576243151XT

• Registered Funds:

  190.31 million yuan

• Website:

  Log in to view

• Email:

  Log in to view